Biogen buys rights to Stoke’s rare epilepsy drug
In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet syndrome.
Biogen bags rights to epilepsy drug from Stoke in $550m deal
Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics in a deal that included an upfront payment of $165 million.
Biogen Bets Up to $550 Million for Rights to Epilepsy Drug
Biogen Inc. has agreed to pay as much as $550 million to develop and sell a drug to treat a genetic seizure disorder, the latest effort by the biotech company to fill holes in its pipeline.
Biogen partners with Stoke Therapeutics on drug for severe epilepsy
Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, outside the U.S.
Biogen, Stoke Therapeutics Ink Deal to Develop Zorevunersen for Dravet Syndrome
Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights to commercialize the treatment outside of North America.
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment
Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet syndrome is a genetic developmental and epileptic encephalopathy characterised by cognitive and behavioural impairments and recurrent seizures.
Biogen gains rights to Stoke’s Dravet syndrome candidate in deal worth $550m
Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet syndrome, with the deal worth $550m.
Biogen, Stoke Therapeutics Set Dravet Syndrome Collaboration
Biogen and Stoke Therapeutics have agreed to collaborate on Stoke's proposed zorevunersen treatment for the severe genetic epilepsy Dravet syndrome in a deal potentially worth hundreds of millions of dollars to Stoke.
Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally
Biogen (NASDAQ:BIIB) and Stoke Therapeutics (NASDAQ:STOK) said on Tuesday they are collaborating to develop and commercialize zorevunersen, an investigational treatment for Dravet syndrome, in territories outside the United States,
National Institute for Health and Care Excellence2d
New life-changing treatment option recommended to help control seizures for type of rare epilepsy
New life-changing treatment option fenfluramine recommended for type of rare epilepsy, Lennox–Gastaut syndrome ...
Gene therapy for rare epilepsy shows promise in mice
Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of ...
Business Wire4d
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with ...
Significant unmet treatment needs remain for patients with Dravet syndrome, a severe ... high-value disease-modifying medicines for rare genetic diseases globally, we aim to lead the treatment ...
openaccessgovernment1d
New NHS treatment offers hope for children with Lennox–Gastaut syndrome
A new treatment option has become available for severe epilepsy: fenfluramine, which is now available on the NHS ...
Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer
Discover Stoke Therapeutics' innovative RNA-based treatments like zorevunersen for Dravet syndrome, with a promising pipeline ...